⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11734409 | 0.67 | — | — | |
| SCHEMBL122102 | 0.67 | — | — | |
| SCHEMBL908521 | 0.67 | — | — | |
| SCHEMBL4108957 | 0.67 | — | — | |
| SCHEMBL538437 | 0.67 | — | — | |
| SCHEMBL128673 | 0.63 | — | — | |
| SCHEMBL8031726 | 0.63 | — | — | |
| SCHEMBL10392930 | 0.62 | — | — | |
| SCHEMBL983305 | 0.62 | — | — | |
| SCHEMBL2379059 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109320505-B | Preparation and application of halogenated butenolide compound with insecticidal activity | 海利尔药业集团股份有限公司 | 2022-08-02 | — | — | CN | disclosed |
| US-7834033-B2 | Methods for treating cancer using 3-[1,3dioxo-4-benzamidoisoindolin-2-yl]-2,6-dioxo-5-hydroxypiperidine | CELGENE CORPORATION (US) | 2010-11-16 | — | — | US | disclosed |
| EP-1733726-B1 | Pharmaceutically active isoindoline derivatives | CELGENE CORP (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1341537-B1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1733726-A1 | Pharmaceutically active isoindoline derivatives | Celgene Corporation (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060069126-A1 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION | 2006-03-30 | — | — | US | disclosed |
| US-7005438-B2 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION (US) | 2006-02-28 | — | — | US | disclosed |
| US-6762195-B2 | TREATING DISEASES MEDIATED BY TUMOR NECROSIS FACTOR; INHIBIT ANGIOGENESIS AND TREATMENT OF CANCER, INFLAMMATORY, AND AUTOIMMUNE DISEASES | CELGENE CORPORATION | 2004-07-13 | — | — | US | disclosed |
| US-20040122052-A1 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION | 2004-06-24 | — | — | US | disclosed |
| EP-1341537-A4 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-1341537-A2 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20030069428-A1 | Pharmaceutically active isoindoline derivatives | MULLER GEORGE | 2003-04-10 | — | — | US | disclosed |
| WO-2002094180-A2 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION (US) | 2002-11-28 | — | — | WO | disclosed |
| US-6458810-B1 | TREATMENT OF DISEASE STATES MEDIATED BY, TNF.ALPHA.. A TYPICAL EMBODIMENT IS TUMOR NECROSIS FACTOR FOR CANCER TREATMENT | CELGENE CORPORATION | 2002-10-01 | — | — | US | disclosed |
| EP-1086064-A2 | DIRECTED COMBINATORIAL COMPOUND LIBRARY AND HIGH THROUGHPUT ASSAYS FOR SCREENING SAME | Glycodesign Inc. (CA) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999064378-A2 | DIRECTED COMBINATORIAL COMPOUND LIBRARY AND HIGH THROUGHPUT ASSAYS FOR SCREENING SAME | GLYCODESIGN INC. (CA) | 1999-12-16 | — | — | WO | disclosed |